OpenAlex
PricingAboutJobs
Log inGet started
Work

A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients

HTML

Year: 2007
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-06-2414
Authors: Isa E.L.M. Kuppens, Els O. Witteveen, Roxanne C. Jewell, Sandra A. Radema, Elaine M. Paul, Steve G. Mangum, Jos H. Beijnen, Emile E. Voest, Jan H.M. Schellens
Institutions: The Netherlands Cancer Institute, University Medical Center Utrecht, GlaxoSmithKline (United States), Utrecht University, Slotervaartziekenhuis
Language: English

Topic: Drug Transport and Resistance Mechanisms
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: elacridar, topotecan, ABCG2, oral bioavailability, drug transport inhibition, dose-limiting toxicity, maximum tolerated dose, dosing regimen, cancer chemotherapy
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2111746410
FWCI: 5.858
Cites: 30
Cited by: 203
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms